On Jul. 31, 2020, Federal Circuit affirmed district court’s
decision which found levothyroxine composition patent invalid as indefinite
under 35 U.S.C. § 112.
Background:
IBSA Institut Biochimique / IBSA Pharma Inc. (Plaintiffs) held NDA
for Tirosint®(levothyroxine sodium) soft gel capsule. Teva (Defendant) filed ANDA with USFDA to market
generic version of Tirosint®. Plaintiffs
sued defendant for infringement of US 7,723,390 patent. The ’390 patent,
entitled “Pharmaceutical Formulations for Thyroid Hormones,” provides pharmaceutical
formulations based on thyroid hormones enabling a safe and stable oral
administration for thyroid disorders. After trial, the district court held claims
1, 2, 4, and 7–9 invalid as indefinite.
Central issue is the parties’ dispute over the construction
of “half-liquid,” which appears in independent claim 1.
1. A pharmaceutical
composition comprising thyroid hormones or their sodium salts in the form of
either: a) a soft elastic capsule consisting of a shell of gelatin material
containing a liquid or half-liquid
inner phase comprising said thyroid hormones or their salts in a range between
0.001 and 1% by weight of said inner phase, dissolved in gelatin and/or
glycerol, and optionally ethanol, said liquid or half-liquid inner phase being in direct contact with said shell
without any interposed layers, or b) a swallowable uniform soft-gel matrix
comprising glycerol and said thyroid hormones or their salts in a range between
0.001 and 1% by weight of said matrix.
IBSA proposed that the term “half-liquid” should be
construed to mean “semi-liquid, i.e., having a thick consistency between solid
and liquid.” Teva argued that the term “half-liquid” is indefinite or should be
construed as “a non-solid, non-paste, non-gel, non-slurry, nongas substance.”
Court’s
analysis:
Federal Circuit first looked at the claim & said that the
claim language of the ’390 patent does not make the meaning of “half-liquid”
reasonably clear. The term “half-liquid” is merely used alongside “liquid” to
describe the inner phase of a soft elastic capsule. Next looking at the
specification, Federal Circuit said that the paragraphs in the specification designate
a “half-liquid” is an alternative to the other members of the list, including
pastes and gels which can be considered a phase between solid & liquid. Therefore,
it is distinct from the “semi-liquid” as suggested by plaintiffs. Plaintiffs
argued that priority (Italian) application is the best source to
understand because the term “semiliquido” appears in the Italian Application as
the same number of times, in the same places, to describe the same things” as
“half-liquid” does in the ’390 patent. A POSA would therefore equate
“semiliquido” with “half-liquid.” But Federal Circuit said that there are
substantial differences between priority aplplication & ‘390 patent. Therefore, POSA would likely consider the
discrepant usage of “half-liquid” and “semiliquido” between the ’390 patent and
the Italian Application to be intentional, implying that the different word
choice has a different scope. In addition to the Italian Application, another
portion of the prosecution history reinforces conclusion that the applicant
intentionally used “half-liquid” instead of “semiliquid.” During the
prosecution of the ’390 patent the applicant had a pending claim using
“half-liquid” and another claim, depending from that claim, using the term
“semi-liquid.” This is additional evidence that the applicant knew the term
“semi-liquid” & “half-liquid” are mean to something different. Thus, the
intrinsic evidence failed to establish the boundaries of a “half-liquid.”
Turning to the extrinsic evidence, Federal Circuit said that
district court correctly held that dictionary definitions and four patents that
predated the ’390 patent are not related to the ’390 patent and therefore do
not provide context for what “half-liquid” means. In addition, the court found
that Dr. Chyall was unable to articulate a boundary for what constitutes a “half-liquid”
and could not tell how a skilled artisan would know when matter is not a
“half-liquid” inner phase. Dr. Chyall was also unsure whether his construction
of “half-liquid” would exclude the types of gel and slurry distinguished during
prosecution.
Federal Circuit thus held that the intrinsic and extrinsic
evidence failed to inform, with reasonable certainty, those skilled in the art
about the scope of the invention. Therefore, claims are invalid as indefinite.
No comments:
Post a Comment